EyenoviaNASDAQ: EYEN

NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced today that it has entered into a securities purchase agreement with an institutional investor and its current largest stockholder, providing for the purchase and sale of 7,575,757 shares of common stock, and warrants to purchase up to 7,575,757 shares of common stock (the "Offering"). The combined offering price for each share of common stock and accompanying warrant is $0.66.

Eyenovia (EYEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Eyenovia, Inc. (NASDAQ:EYEN) Q1 2024 Results Conference Call on May 14, 2024 at 4:30 PM ET with Company Representatives Eric Ribner, Michael Rowe, John Gandolfo, and Bren Kern. Conference Call Participants include Matt Kaplan, Matthew Caufield, and Kemp Dolliver from Ladenburg, H.C. Wainwright, and Brookline Capital Markets, respectively. Operator: Good afternoon, everyone, and thank you for joining the Eyenovia First Quarter 2024 Earnings Conference Call.

Eyenovia (EYEN) drops 18% following the announcement of potential strategic alternatives, including the sale of the company or assets, due to financial difficulties and underperformance of existing drugs.

Eyenovia, Inc. (EYEN) Q4 2023 Earnings Call Transcript

Eyenovia, Inc. (EYEN) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago.

Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT

The U.S. Food and Drug Administration approved Eyenovia's eye drops to reduce inflammation and pain in patients who have undergone eye surgery, Formosa Pharmaceuticals said on Monday.

Eyenovia has received FDA approval for its Optejet system, which revolutionizes how eye medications are dosed, resolving limitations and adverse events caused by traditional eye droppers. The company's manufacturing facilities, including two in the USA and one in Mexico, have received FDA certification, ensuring the safety and quality of their products. Eyenovia is preparing for the official launch of its first FDA-approved product, MydCombi, and has upcoming events, including financial results and an FDA decision for another drug.